Novozymes Delta

Albumedix, formerly known as Novozymes Delta, is a biopharmaceutical company specializing in recombinant human albumin-based solutions. The company provides high-purity, animal-free recombinant albumin (Recombumin) used as an excipient for stabilizing vaccines, cell therapies, and other biopharmaceuticals. Their proprietary Veltis platform enables the half-life extension of therapeutic proteins and peptides through genetic fusion or chemical conjugation to engineered albumin variants. Based in Nottingham, UK, the company was originally founded as Delta Biotechnology before being acquired by Novozymes and later by Sartorius in 2022. Albumedix's technologies are integrated into numerous commercialized products and clinical-stage candidates across the global pharmaceutical industry.